aTyr Pharma (471A) Stock Overview
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
471A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$0.47 |
| Beta | 0.56 |
| 1 Month Change | 0.81% |
| 3 Month Change | 25.50% |
| 1 Year Change | -82.04% |
| 3 Year Change | -63.77% |
| 5 Year Change | -83.81% |
| Change since IPO | -98.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 471A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.0% | 0.5% | -2.7% |
| 1Y | -82.0% | -8.0% | -3.9% |
Return vs Industry: 471A underperformed the German Biotechs industry which returned 2.7% over the past year.
Return vs Market: 471A underperformed the German Market which returned -2.6% over the past year.
Price Volatility
| 471A volatility | |
|---|---|
| 471A Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 471A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 471A's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 59 | Sanjay Shukla | atyrpharma.com |
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
aTyr Pharma, Inc. Fundamentals Summary
| 471A fundamental statistics | |
|---|---|
| Market cap | €69.01m |
| Earnings (TTM) | -€64.01m |
| Revenue (TTM) | €164.08k |
Is 471A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 471A income statement (TTM) | |
|---|---|
| Revenue | US$190.00k |
| Cost of Revenue | US$60.22m |
| Gross Profit | -US$60.03m |
| Other Expenses | US$14.09m |
| Earnings | -US$74.12m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | -31,594.21% |
| Net Profit Margin | -39,009.47% |
| Debt/Equity Ratio | 0% |
How did 471A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/19 06:06 |
| End of Day Share Price | 2026/03/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
aTyr Pharma, Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Ilya Zubkov | Freedom Broker |